Notably, molecular subtype association analysis of transcriptional profiles from clinical breast cancer samples revealed that embigin expression was low specifically in basal-like, ER-/HER2- patients, in which 46% basal-like tumors expressed the lowest levels of embigin consistent with a potential role for embigin in this subtype (Figure 7D, 7E & 7F). This evidence concerns the gene ERBB2 and breast carcinoma.